Grant
Revotar Biopharmaceuticals AG has been awarded €2.5 million by the German Federal State of Brandenburg for the development of its pipeline of selectin antagonists in respiratory indications as part of the European Regional Development Fund programme.
“The funds will mainly be used to advance our preclinical and clinical programmes of anti-inflammatory drugs for the treatment of chronic obstructive pulmonary disease (COPD),” said Wolfgang Meyer-Sabellek, Chief Medical Officer of Revotar.
Revotar’s lead candidate Bimosiamose successfully completed Phase IIa trials in asthma, COPD and psoriasis, demonstrating excellent safety and efficacy profiles. A further phase IIa study of Bimosiamose in COPD is scheduled to start in 2010.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
